Published in Oncogene on October 29, 2007
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem (2008) 10.08
SMAD proteins control DROSHA-mediated microRNA maturation. Nature (2008) 9.67
miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res (2008) 8.97
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
miR-21: a small multi-faceted RNA. J Cell Mol Med (2009) 5.59
MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer (2009) 5.47
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol (2008) 5.21
Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol (2009) 5.05
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80
Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst (2013) 4.03
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell (2010) 3.72
Integrating mechanisms of pulmonary fibrosis. J Exp Med (2011) 3.57
Non-coding RNAs as regulators of embryogenesis. Nat Rev Genet (2011) 3.36
MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol (2009) 3.19
MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet (2010) 3.12
MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell (2008) 3.10
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
microRNA involvement in human cancer. Carcinogenesis (2012) 2.98
miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One (2009) 2.97
MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol (2009) 2.89
MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics (2010) 2.80
A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One (2010) 2.64
MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer (2009) 2.57
Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol (2009) 2.57
The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol (2009) 2.56
Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res (2009) 2.52
MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem (2010) 2.49
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer (2009) 2.45
Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res (2009) 2.45
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res (2009) 2.43
AngiomiRs--key regulators of angiogenesis. Curr Opin Genet Dev (2009) 2.40
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res (2009) 2.32
Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci U S A (2010) 2.31
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer (2010) 2.10
Involvement of MicroRNAs in hydrogen peroxide-mediated gene regulation and cellular injury response in vascular smooth muscle cells. J Biol Chem (2009) 2.08
MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol (2010) 2.05
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther (2009) 2.01
MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med (2008) 1.99
Regulation and function of miRNA-21 in health and disease. RNA Biol (2011) 1.99
miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet (2010) 1.97
MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem (2010) 1.94
New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) (2008) 1.94
MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One (2011) 1.90
High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis (2010) 1.87
MicroRNA-204/211 alters epithelial physiology. FASEB J (2010) 1.83
Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol (2010) 1.83
Distinct passenger strand and mRNA cleavage activities of human Argonaute proteins. Nat Struct Mol Biol (2009) 1.81
Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes (2010) 1.80
Induction of microRNA-155 is TLR- and type IV secretion system-dependent in macrophages and inhibits DNA-damage induced apoptosis. Proc Natl Acad Sci U S A (2012) 1.79
MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther (2011) 1.77
Apoptosis and the target genes of microRNA-21. Chin J Cancer (2011) 1.74
Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res (2010) 1.74
Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol (2013) 1.73
Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer (2010) 1.72
microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep (2012) 1.68
Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene (2011) 1.67
Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci U S A (2011) 1.64
Epstein-Barr virus growth/latency III program alters cellular microRNA expression. Virology (2008) 1.63
MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-kappaB signaling. Am J Physiol Gastrointest Liver Physiol (2010) 1.62
MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One (2011) 1.61
Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ (2013) 1.60
Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol (2010) 1.58
miR-21: an oncomir on strike in prostate cancer. Mol Cancer (2010) 1.54
Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta (2014) 1.53
Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem (2009) 1.53
MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol (2010) 1.52
CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a. PLoS One (2013) 1.51
Causes and consequences of microRNA dysregulation. Cancer J (2012) 1.51
Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal (2011) 1.50
RNA-binding protein HuR sequesters microRNA-21 to prevent translation repression of proinflammatory tumor suppressor gene programmed cell death 4. Oncogene (2015) 1.50
Melanoma miRNA trafficking controls tumour primary niche formation. Nat Cell Biol (2016) 1.49
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA (2009) 1.48
MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem (2011) 1.46
MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One (2012) 1.45
The role of microRNAs in colorectal cancer. Cancer J (2012) 1.44
MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem (2013) 1.43
MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem (2012) 1.43
Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer (2009) 1.42
An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int J Cancer (2014) 1.42
Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines. Oncol Rep (2012) 1.41
n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis (2009) 1.41
Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res (2010) 1.40
MicroRNA and colorectal cancer. World J Surg (2009) 1.40
MicroRNA Involvement in Osteosarcoma. Sarcoma (2012) 1.38
Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro Oncol (2011) 1.38
Structural basis for translational inhibition by the tumour suppressor Pdcd4. EMBO J (2009) 1.38
Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med (2011) 1.38
MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer (2010) 1.38
Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. Mol Cancer (2010) 1.37
MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J (2009) 1.37
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer (2011) 1.35
MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev (2012) 1.34
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene (2008) 4.43
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol (2004) 3.56
Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A (1994) 2.43
Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res (1978) 2.23
Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A (1999) 2.19
A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene (2001) 2.08
Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proc Natl Acad Sci U S A (1981) 1.84
Tumour promoter induces anchorage independence irreversibly. Nature (1979) 1.83
Hepatic microcirculatory perfusion failure is a determinant of liver dysfunction in warm ischemia-reperfusion. Am J Pathol (1994) 1.75
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene (2011) 1.75
Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer. Eur J Surg Oncol (2000) 1.73
Family-centered maternity care: the Canadian picture. Dimens Health Serv (1981) 1.65
AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science (1989) 1.63
Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene (2007) 1.62
Molecular cloning of five messenger RNAs differentially expressed in preneoplastic or neoplastic JB6 mouse epidermal cells: one is homologous to human tissue inhibitor of metalloproteinases-3. Cancer Res (1994) 1.57
MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene (2011) 1.57
Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med (2000) 1.53
[S3-guideline colorectal cancer version 1.0]. Z Gastroenterol (2013) 1.51
Temporary cystogastrostomy with self-expanding metallic stents for pancreatic necrosis. Endoscopy (2010) 1.48
Transgastric appendicectomy. Br J Surg (2013) 1.46
Ischaemic preconditioning by partial occlusion without intermittent reperfusion. Cardiovasc Res (1994) 1.44
TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine (1997) 1.42
Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res (1996) 1.41
[Elective colon resection in Germany. A survey of the perioperative anesthesiological management]. Anaesthesist (2007) 1.39
Is radical scavenging necessary in the treatment of inflammatory bowel disease? Gastroenterology (1991) 1.39
Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res (1997) 1.36
An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (1992) 1.33
Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis (1996) 1.32
Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med (1995) 1.30
A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol Carcinog (1997) 1.27
Comparison of two-stage epidermal carcinogenesis initiated by 7,12-dimethylbenz(a)anthracene or N-methyl-N'-nitro-N-nitrosoguanidine in newborn and adult SENCAR and BALB/c mice. Cancer Res (1981) 1.26
Differential responsiveness to CD3-Ti vs. CD2-dependent activation of human intestinal T lymphocytes. Eur J Immunol (1990) 1.25
The binding of beta-propiolactone to mouse skin DNA in vivo; its correlation with tumor-initiating activity. Cancer Res (1966) 1.25
Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer (2007) 1.23
Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet (1990) 1.23
Aerosol-delivered programmed cell death 4 enhanced apoptosis, controlled cell cycle and suppressed AP-1 activity in the lungs of AP-1 luciferase reporter mice. Gene Ther (2007) 1.22
Increased expression of adenylylcyclase type VI proportionately increases beta-adrenergic receptor-stimulated production of cAMP in neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A (1998) 1.17
Transformation reversion induced in JB6 RT101 cells by AP-1 inhibitors. Carcinogenesis (1995) 1.15
Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene (1998) 1.15
PCR-direct sequencing of a GC-rich region by inclusion of 10% DMSO: application to mouse c-jun. Biotechniques (1993) 1.13
QuickMap: a public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Ther (2009) 1.11
Role of microcirculatory derangements in manifestation of portal triad cross-clamping-induced hepatic reperfusion injury. J Surg Res (1996) 1.11
Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53. Oncogene (2008) 1.10
Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion. Oncogene (2010) 1.09
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer (2007) 1.06
Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes. Mol Carcinog (2000) 1.05
Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene (2009) 1.03
Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation. Cancer Res (2001) 1.03
Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene (1998) 1.03
Hepatic arteriolo-portal venular shunting guarantees maintenance of nutritional microvascular supply in hepatic arterial buffer response of rat livers. J Physiol (2001) 1.02
AP-1/jun is required for early Xenopus development and mediates mesoderm induction by fibroblast growth factor but not by activin. J Biol Chem (1996) 1.02
Local excision of early rectal cancer: is transanal endoscopic microsurgery an alternative to radical surgery? Rev Esp Enferm Dig (2009) 1.00
A cell culture assay for tumor-promoter-dependent progression toward neoplastic phenotype: detection of tumor promoters and promotion inhibitors. Teratog Carcinog Mutagen (1980) 1.00
Tumor-promoting phorbol esters inhibit procollagen synthesis at a pretranslational level in JB-6 mouse epidermal cells. Mol Cell Biol (1983) 1.00
Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. FASEB J (1993) 1.00
Molecular cloning of mouse tissue inhibitor of metalloproteinases-3 and its promoter. Specific lack of expression in neoplastic JB6 cells may reflect altered gene methylation. J Biol Chem (1995) 0.99
Differential c-jun expression in response to tumor promoters in JB6 cells sensitive or resistant to neoplastic transformation. Mol Carcinog (1992) 0.98
Tumor promotion and preneoplastic progression. Carcinog Compr Surv (1980) 0.98
Extrahepatic biliary obstruction impairs microvascular perfusion and increases leukocyte adhesion in rat liver. Hepatology (1997) 0.97
Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol (1995) 0.97
Role of reactive oxygen in tumor promotion: implication of superoxide anion in promotion of neoplastic transformation in JB-6 cells by TPA. Carcinogenesis (1985) 0.97
Inhibition of AP-1 and NF-kappaB by manganese-containing superoxide dismutase in human breast cancer cells. FASEB J (1998) 0.96
Isolation and partial characterization of a transformation-associated sequence from human nasopharyngeal carcinoma. Mol Carcinog (1991) 0.96
Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem (2000) 0.96
Retinoids inhibit promoter-dependent preneoplastic progression in mouse epidermal cell lines. Ann N Y Acad Sci (1981) 0.96
Drug-induced fibrosing colonopathy in inflammatory bowel disease after 5-ASA? Dig Dis Sci (1999) 0.95
Four-day duration of tumor promoter exposure required to transform JB6 promotion-sensitive cells to anchorage independence. Cancer Res (1988) 0.95
Biodegradation of absorbable sutures in body fluids and pH buffers. Eur Surg Res (2004) 0.94
A family of mitogen-activated protein kinase-related proteins interacts in vivo with activator protein-1 transcription factor. J Biol Chem (1994) 0.93
Nasopharyngeal carcinoma shows no detectable retinoblastoma susceptibility gene alterations. Oncogene (1993) 0.93
Studies of the reaction of beta-propiolactone with deoxyguanosine and related compounds. Biochem Pharmacol (1965) 0.92
Acquisition of a growth-inhibitory response to phorbol ester involves DNA damage. Cancer Res (1992) 0.92
Vanadate-induced activation of activator protein-1: role of reactive oxygen species. Carcinogenesis (1999) 0.92
A new technique of endoscopic full-thickness resection using a flexible stapler. Endoscopy (2006) 0.92
Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg (1997) 0.91
Fluorescence lifetime imaging microscopy of chemotherapy-induced apoptosis resistance in a syngenic mouse tumor model. Int J Cancer (2010) 0.91
Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol (2000) 0.91
Ileus secondary to wireless capsule enteroscopy. Int J Colorectal Dis (2006) 0.91
Impact of N-acetylcysteine on the hepatic microcirculation after orthotopic liver transplantation. Transplantation (1996) 0.91
Role of cytoskeleton changes and expression of the H-ras oncogene during promotion of neoplastic transformation in mouse epidermal JB6 cells. Cancer Res (1986) 0.90
Is delayed gastric emptying following pancreaticoduodenectomy related to pylorus preservation? Langenbecks Arch Surg (1999) 0.90
Clostridial gas gangrene of the abdominal wall after laparoscopic cholecystectomy. J Laparoendosc Adv Surg Tech A (1997) 0.90
Malignant intestinal non-Hodgkin's lymphoma from the surgical point of view. Onkologie (2002) 0.90
Inhibition of nitric oxide synthesis in ischemia/reperfusion of the rat liver is followed by impairment of hepatic microvascular blood flow. J Hepatol (1997) 0.90
C-JUN/AP-1 as possible mediators of tumor necrosis factor-alpha-induced apoptotic response in mouse JB6 tumor cells. Oncol Res (1995) 0.90
Influence of autologous blood transfusion on natural killer and lymphokine-activated killer cell activities in cancer surgery. Vox Sang (1997) 0.90
Early superoxide dismutase-sensitive event promotes neoplastic transformation in mouse epidermal JB6 cells. Carcinogenesis (1988) 0.90
Selective fluid cushion in the submucosal layer by water jet: advantage for endoscopic mucosal resection. Eur Surg Res (2007) 0.89
Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor? Clin Investig (1993) 0.89
Involvement of Ras/Raf/AP-1 in BMP-4 signaling during Xenopus embryonic development. Proc Natl Acad Sci U S A (1996) 0.89
Prognostic influence of blood transfusion on minimal residual disease in resected gastric cancer patients. Anticancer Res (1997) 0.89
A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. Eur J Biochem (1999) 0.89
Retrorectal tumors: excision by transanal endoscopic microsurgery. Rev Esp Enferm Dig (2007) 0.89
Impact of gastrin-releasing peptide on intestinal microcirculation after ischemia-reperfusion in rats. Digestion (2000) 0.89
Differential transformation efficiency but not AP-1 induction under anchorage-dependent and -independent conditions. Carcinogenesis (1994) 0.89
Endoscopic full-thickness resection of the stomach: an experimental approach. Surg Endosc (2006) 0.88
[Open abdomen 2009. A national survey of open abdomen treatment in Germany]. Chirurg (2011) 0.88